The Prolia® Patient

Who is affected by osteoporosis in Canada?

Early detection

Down arrow

Osteoporosis in Canada

Many women and men will suffer from osteoporosis in their lifetime. Early detection and appropriate therapy are important.1

There are two similar tools available to Canadian physicians for estimating patients' 10-year fracture risk. The first is the updated tool of the Canadian Association of Radiologists and Osteoporosis Canada (CAROC). The second is the Canadian Fracture Risk Assessment tool from the World Health Organization (WHO) (FRAX). Both tools are available at osteoporosis.ca in the Healthcare Providers section under Tools.

These tools use the bone mineral density or T-score for the femoral neck only. They have been calibrated using the same Canadian fracture data and have been directly validated in Canadians.1

Prolia can be used to increase bone mass in men with osteoporosis at high risk for fracture.2*

Consider Prolia for your osteoporosis patients at high risk for fracture

Prolia (denosumab injection) is indicated:2

  1. for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia reduces the incidence of vertebral, nonvertebral and hip fractures.
  2. as a treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
  3. as a treatment to increase bone mass in men with nonmetastatic prostate cancer receiving androgen deprivation therapy (ADT), who are at high risk for fracture.
  4. as a treatment to increase bone mass in women with nonmetastatic breast cancer receiving adjuvant aromatase inhibitor (AI) therapy, who have low bone mass and are at high risk for fracture.
  5. as a treatment to increase bone mass in women and men at high risk for fracture due to sustained systemic glucocorticoid therapy.
  6. as a treatment to increase bone mass in women and men at high risk for fracture who are starting or have recently started long-term glucocorticoid therapy.
Additional Resources
Clinical Practice Guidelines Icon
Clinical Practice Guidelines

Access the 2010 Osteoporosis Clinical Practice Guidelines in the virtual library.

Virtual LibraryArrow Image
References

You are now leaving the Prolia.ca website.

The linked sites are not under the control of Amgen, and Amgen is not responsible for the content available on the linked sites. Such links do not imply Amgen's endorsement of material on any other site, and Amgen disclaims all liability with regard to your access to such linked websites. Amgen provides links to other Internet sites as a convenience to users, and access to such linked sites is at your own risk.

Do you want to link to our other external sites and leave Prolia.ca?

You are now leaving the Prolia.ca website. Please note that the information you are about to view may not comply with Canadian regulatory requirements. Marketing authorizations and availability of products may differ between Canada and other countries.

Proceed